Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2022 - nature.com
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore, C Krishna… - paper.sciencenet.cn
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

[引用][C] Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2021 - cir.nii.ac.jp
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2021 - europepmc.org
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

[HTML][HTML] Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2022 - ncbi.nlm.nih.gov
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …